Market Currents
Jazz Pharmaceuticals (JAZZ) keeps soaring, now up 15.4% premarket after AH strength, on the...
-
Friday, April 27, 2012, 9:12 AM ETJazz Pharmaceuticals (JAZZ) keeps soaring, now up 15.4% premarket after AH strength, on the heels of landing EUSA Pharma and its leukemia drug for a cool $700M. The deal gives the company a larger global footprint.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
